Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Patients with hematological malignancy and COVID-19 display a high mortality rate. In such
patients, immunosuppression due to underlying disease and previous specific treatments …

Although severe coronavirus disease 2019 (COVID-19) and death from COVID-19 are
generally preventable in immunocompetent people in areas of the world with sufficient …

In this short narrative, we highlight some of our experiences leading the US Convalescent
Plasma Program at the beginning of the pandemic in the spring and summer of 2020. This …

In this review we highlight the contributions of passive experiments that address important
exercise related questions in integrative physiology and medicine. Passive experiments …

Therapeutic antibodies have broad indications across diverse disease states, such as
oncology, autoimmune diseases, and infectious diseases. New research continues to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept across the world in
the waning months of 2019 and emerged as the cause of the coronavirus disease 19 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains an ongoing
therapeutic challenge among patients with antibody deficiencies, herein referred to as …